Introduction
Renal cell carcinoma accounts for 80% of all kidney cancers -worldwide; the tumor staging at diagnosis ranges from small, low-stage tumors to more advanced neoplasms [1] [2] [3] [4] [5] . The survival rate has increased in recent years: nowadays, patients with localized disease have a 5-year survival >80% but in those with distant metastatic RCC, 5-year survival is <10% [6] [7] [8] . The increase in overall survival was due, at least in part, to improved surgical techniques [9, 10] . Until recently cytokines (interleukin-2 or interferon-alpha), were the mainstay of systemic treatment despite low response rates and significant toxicity [11, 12] .
Since 2005, six targeted therapies for advanced/metastatic RCC were approved by both the FDA and EMA: three are multitargeted tyrosine kinase inhibitors (TKIs), sorafenib (SO), sunitinib (SU) and pazopanib (PZ), two are oral mTOR inhibitors, temsirolimus (TS) and everolimus (EV) and one is the anti-VEGF monoclonal antibody bevacizumab (BV), administered in combination with IFN-alpha [13] . These new agents improved the progression free survival (PFS) and the overall survival (OS) in several subgroups of patients; however, expert opinion on the optimal therapeutic strategy is divided.
Two main therapeutic approaches-use of these new agents in combination or sequentially-have been studied to increase efficacy and tolerability. Sequential therapy is the current standard of care in the treatment of advanced RCC as existing combination regimens have a high incidence of adverse events without a substantial increase in efficacy. The use of sequential therapy provides a number of important advantages: patients who are refractory to one or more targeted agent(s) may benefit from treatment with a different agent; there is no/limited cross-resistance between agents and patients experiencing disease progression with one anti-angiogenic agent can subsequently benefit from treatment with another [14, 15] .
The results of recent phase III randomized controlled trials (RCTs) prompted the National Comprehensive Cancer Network (NCCN) and the European Association of Urology (EAU) to update their clinical practice guidelines for the treatment of metastatic RCC [16, 17] . The EAU recommended SU as a first-line therapy in low-and intermediate-risk patients and www.intechopen.com concluded that SO is effective as second-line treatment after failure of cytokine therapy or in patients unfit for cytokines [18] . Clinical evidence supports the efficacy of sequential treatment with SU/SO [19] ; however, the optimal sequence for SO and SU is still under debate, and additional evidence on the optimal use of sequential targeted therapies is advocated.
In this retrospective study -the preliminary results of which have been previously presented [20] -the safety and efficacy of different sequential schemes of targeted therapies, in patients with advanced/metastatic RCC were studied.
Methods

Patients
This retrospective study was conducted at the 'Istituto Nazionale Tumori of Milan' (National Institute of Tumors, Milan, Italy) -one of the most important Italian institutions for cancer diagnosis and treatment -between January 2004 and July 2010. Patients were patients aged ≥18 years with advanced/metastatic RCC and a life expectancy of >3 months who had been treated with antiangiogenic therapy (one or more) were eligible for enrollment in this retrospective study. Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2 were included. A number of patients enrolled in this study had previously taken part in a range of prospective trials including TARGET , the EU-ARCCS , RECORD-1 , AXIS , AVOREN and ROSORC at our centre.
Treatment
Patients received a range of different systemic agents -SO, SU, BV, EV, TS and axitinib (AX) alone or in combination, and could have received a previous treatment with cytokines. SO was administered orally at a dose of 400 mg twice daily and SU at a daily dose of 50 mg orally with a 4 weeks on 2 weeks off schedule. BV was administered iv at 10 mg/Kg every 2 weeks in combination with Interferon-a subcutaneously, EV was administered orally at 10 mg daily continuously, TS iv weekly at 25 mg/dose and AX at 10 mg/daily orally continuously. Patients received systemic therapy until disease progression or the presence of serious adverse events.
Study assessments
Study assessments were conducted at baseline and once a month thereafter. Baseline characteristics were taken ≤28 days after the start of treatment. Drug safety and tolerability were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCTCA version 3). Efficacy was assessed by progression-free survival (PFS) and overall survival (OS) according to the Motzer classification [21] . PFS was defined as the time from start of systemic treatment to death or disease progression whichever occurred first. Disease progression was evaluated using the Response Evaluation criteria in Solid Tumours (RECIST, version 1.0) by the treating physician. Assessments were performed monthly (every 3 weeks for patients on sunitinib, due to the schedule of administration for this drug). Patients with Bellini duct RCC were excluded from the efficacy analysis, due to the different histology of the tumor.
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Statistical analyses
All clinical and instrumental variables and toxicity data were analyzed by descriptive statistics: mean, standard deviation, minimum, and maximum values for continuous variables, and absolute and relative frequencies for categorical variables. Curves relevant to OS (overall, Motzer and according to therapy option) were estimated by the Kaplan-Meier method and compared by means of the log-rank test. Reports of AEs were categorized according to type, severity, and outcome. A p value <0.05 was considered statistically significant.
Results
A total of 310 patients with metastatic RCC were observed, and followed-up for a median of 37 months (range 21-49 months). Patient characteristics at baseline are shown in Table 1 
Adverse events
The most commonly reported treatment-related all grade adverse events (AEs) were typical of those reported with TKIs including asthenia, hand-foot syndrome, hypertension, diarrhea, mucositis, hypothyroidism and most of these were mild or moderate in intensity (Grade 1 or 2). Overall, 61 (19.68%) patients experienced AEs Grade ≥3 ( Table 4) and there were a total of 65 Grade ≥3 AEs, and three patients experienced a Grade 4 event (two patients receiving SU+SO had cardiac failure and one receiving SO+SU had a cardiac stroke). The percentage of patients experiencing adverse events Grade ≥3 was similar in patients treated when SO was given as in those treated first with SU then SO (18.88 and 17.46%). In those treated with other systemic therapies there was a tendency to a higher incidence of AEs (25.5%). Furthermore the nature and severity of AEs groups did not differ if SO or SU was given first.
Adjusted for Motzer criteria Not adjusted for Motzer criteria
Hazard ratio (95% CI) 
Discussion
Despite improvements in therapy, RCC eventually progresses during therapy and other agent(s) need to be administered in an attempt to control the disease.
This large-scale retrospective analysis was carried out to investigate the effects of systemic therapy in general and in particular to compare the efficacy and safety of different sequential approaches with targeted therapies in controlling the disease progression of patients with RCC. Importantly, our results show that treatment with TKIs improves survival. In fact the median OS for patients with advanced RCC has increased from around 13 months before the introduction of TKIs to around 22 months in the last decade and the median OS of 22 months observed in the present study provides further evidence to support the importance of use of TKI in patients with advanced RCC. In addition, to our knowledge most studies have considered PFS, and not OS, as the major determinant of clinical efficacy of any sequential therapy for the treatment of RCC: our study provides new evidence on OS even in a large unselected population from a single institution. Of note, a relevant proportion of patients received sorafenib as a first-line agent, despite current recommendations suggest this molecule as a second-line treatment, and sunitinib at progression of disease. This therapeutic strategy did not result in any worsening of clinical outcomes and in a similar tolerability with respect to the other therapeutic strategies assessed. Even if this study was not designed to evaluate the feasibility of sorafenib as a first-line agent, and therefore we are unable to draw any conclusion, we believe that this finding could be of some interest in the current therapeutic scenario of RCC patients.
In addition, the Motzer criteria resulted significant prognostic factors in both the uni-and multi-variate analysis. On this basis, we suggest that these criteria should -at present -be regarded to as the most useful tool for the definition of prognosis and, as a consequence, for the optimization of therapy for every single patient.
Of note, the findings reported in the present report were obtained in a real-life scenario, on a large population of unselected patients: it has been suggested that observational trials can expand upon outcomes of randomized controlled trials, which are necessarily conducted in highly-selected patients [22] .
In most patients with advanced RCC the objective of treatment is to stabilize disease and prolong survival and there is good evidence that this can be achieved with sequencing systemic agents. The use of this therapeutic approach, in fact, may determine a relevant benefit in terms of OS and quality of life, independently from the specific sequence of targeted therapies used.
Our study confirms the suitability of a TKI sequential therapy. This finding is in line with recent evidence, albeit collected in retrospective studies, which seems to support that the use of SO before SU, rather than vice versa may be more effective in extending PFS ( Table 5 ). In addition, some studies suggest that SO may be associated with a more favorable safety profile than more potent SU, in terms of incidence of changes in blood counts and anemia [23, 24] .
The major limitations of the current study was that the sample size was not randomized and the data were collected retrospectively. In addition the study populations were very hoeterogenous with much patients received the sequence TKI followed TKI and only few cases treated with bevacizumab, everolimus, temsirolimus and axitinib. In conclusion, despite the major breakthrough introduced by targeted therapies, further research is necessary to shed new lights on the most effective use of these drugs in clinical practice: in particular, the optimal sequence of TKIs has yet to be established.
Our study supports -however -the importance of TKI treatment in RCC patients to improve OS. In addition, it suggests that factors other than the specific sequence of treatment, like the Motzer classification, influence the OS in a large unselected population from clinical practice collected in a single institution. On the basis of these results and of current evidence reported in literature is now clear that there is not one therapy that will benefit all patients and treatment should be tailored to meet individual circumstances and needs. Physicians should therefore base their treatment decisions not only on data from RCTs but also on clinical experience and judgment The field of renal cell cancer has undergone a significant resurgence. This book summarizes up-to-date research and innovative ideas for the future in this rapidly changing field, which encompasses medicine, surgery, radiation oncology, basic science, pathology, radiology, and supportive care. This book is aimed at the clinician or scientist who has an interest in renal cell cancer, whether they are academic or nonacademic. The book covers tumor biology, molecular biology, surgery techniques, radiation therapy, personal testimonies, and present and future treatments of the disease that are on the horizon. The goal was to produce a textbook that would act as an authoritative source for scientists and clinicians and interpret the field for trainees in surgery, medicine, radiation oncology, and pathology.
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